Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Oct 12, 2023 9:15pm
106 Views
Post# 35681558

RE:RE:Tesamorelin

RE:RE:TesamorelinA couple of years ago the company was invited to a panel discussion with some other companies including MDGL and I remember the CEO invited other companies to join THTX in a combo trial, since then they have altered their NASH trial from phase 3 to now phase 2B/3 in order to reduce the costs and risks trying to make it more feasible for potential partners but so far no bites. The issue is even the feasibility trials especially for NASH is costly and lengthy. Maybe another serious attempt by the company's scientists would attract more attention. I would love to see after all these years they would end up with a decent deal....
Joemare wrote: They need to plant seeds for a combo trial.  Regeron,, Novo, etc...plant seeds. Get Grinspoon out there. THey need to get their medical liason dudes working harder. 


<< Previous
Bullboard Posts
Next >>